CSPC announced that it has received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026. Previously, the company received the down payment under the agreement on May 29, 2026. The agreement aims to develop innovative long-acting peptide drugs using CSPC Group's long-term delivery technology platform and peptide drug AI discovery platform.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.